Trimegestone

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 461513

CAS#: 74513-62-5

Description: Trimegestone is a highly effective oral progestogen for endometrial protection, all doses inducing secretory endometrial transformation.

Chemical Structure

img
Trimegestone
CAS# 74513-62-5
Instruction

Theoretical Analysis

MedKoo Cat#: 461513
Name: Trimegestone
CAS#: 74513-62-5
Chemical Formula: C22H30O3
Exact Mass: 342.22
Molecular Weight: 342.470
Elemental Analysis: C, 77.16; H, 8.83; O, 14.01

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Trimegestone; RU 27987; RU-27987; RU27987;

IUPAC/Chemical Name: (8S,13S,14S,17S)-17-(2-hydroxypropanoyl)-13,17-dimethyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one

InChi Key: JUNDJWOLDSCTFK-PSEXJEBXSA-N

InChi Code: InChI=1S/C22H30O3/c1-13(23)20(25)22(3)11-9-19-18-6-4-14-12-15(24)5-7-16(14)17(18)8-10-21(19,22)2/h12-13,18-19,23H,4-11H2,1-3H3/t13?,18-,19+,21+,22-/m1/s1

SMILES Code: C[C@@]12[C@@](C)(C(C(C)O)=O)CC[C@@]1([H])[C@]3([H])CCC4=CC(CCC4=C3CC2)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 342.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Marques Lde O, Cordeiro Júnior DG, Lago VV, Carvalho SL, Collaço LM, Sobral AC. [Effect of trimegestone on mammary gland of castrated rats]. Rev Bras Ginecol Obstet. 2011 Jul;33(7):137-42. Portuguese. PubMed PMID: 22012423.

2: Philibert D, Bouchoux F, Degryse M, Lecaque D, Petit F, Gaillard M. The pharmacological profile of a novel norpregnance progestin (trimegestone). Gynecol Endocrinol. 1999 Oct;13(5):316-26. PubMed PMID: 10599548.

3: Al-Azzawi F, Wahab M, Thompson J, Whitehead M, Thompson W. Acceptability and patterns of uterine bleeding in sequential trimegestone-based hormone replacement therapy: a dose-ranging study. Hum Reprod. 1999 Mar;14(3):636-41. PubMed PMID: 10221688.

4: Wahab M, Thompson J, Al-Azzawi F. The distribution of endometrial leukocytes and their proliferation markers in trimegestone-treated postmenopausal women compared to the endometrium of the natural cycle: a dose-ranging study. Hum Reprod. 1999 May;14(5):1201-6. PubMed PMID: 10325261.

5: Hellgren M, Conard J, Norris L, Kluft C. Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone. Maturitas. 2009 Mar 20;62(3):287-93. doi: 10.1016/j.maturitas.2009.01.004. Epub 2009 Mar 5. PubMed PMID: 19268506.

6: Norris LA, Brosnan J, Bonnar J, Conard J, Kluft C, Hellgren M. Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestone. Thromb Haemost. 2008 Aug;100(2):253-60. PubMed PMID: 18690345.

7: al-Azzawi F, Wahab M, Thompson J, Pornel B, Hirvonen E, Ylikorkala O, van der Mooren MJ, Dillon J, Magaril C. Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical sequential combinations of trimegestone or norethisterone acetate. Climacteric. 2001 Dec;4(4):343-54. PubMed PMID: 11770191.

8: Ross D, Godfree V, Cooper A, Pryse-Davies J, Whitehead MI. Endometrial effects of three doses of trimegestone, a new orally active progestogen, on the postmenopausal endometrium. Maturitas. 1997 Sep;28(1):83-8. PubMed PMID: 9391999.

9: Al-Azzawi F, Wahab M, Sami S, Proudler AJ, Thompson J, Stevenson J. Randomized trial of effects of estradiol in combination with either norethisterone acetate or trimegestone on lipids and lipoproteins in postmenopausal women. Climacteric. 2004 Sep;7(3):292-300. PubMed PMID: 15669554.

10: Wahab M, Al-Azzawi F. Trimegestone: expanding therapeutic choices for the treatment of the menopause. Expert Opin Investig Drugs. 2001 Sep;10(9):1737-44. Review. PubMed PMID: 11772282.

11: Wahab M, Thompson J, Whitehead M, Al-Azzawi F. The effect of a change in the dose of trimegestone on the pattern of bleeding in estrogen-treated post-menopausal women: 6 month extension of a dose-ranging study. Hum Reprod. 2002 May;17(5):1386-90. PubMed PMID: 11980769.

12: Grubb G, Spielmann D, Pickar J, Constantine G. Clinical experience with trimegestone as a new progestin in HRT. Steroids. 2003 Nov;68(10-13):921-6. Review. PubMed PMID: 14667984.

13: Wahab M, Thompson J, Hamid B, Deen S, Al-Azzawi F. Endometrial histomorphometry of trimegestone-based sequential hormone replacement therapy: a weighted comparison with the endometrium of the natural cycle. Hum Reprod. 1999 Oct;14(10):2609-18. PubMed PMID: 10527996.

14: Bouali Y, Gaillard-Kelly M, Marie PJ. Effect of trimegestone alone or in combination with estradiol on bone mass and bone turnover in an adult rat model of osteopenia. Gynecol Endocrinol. 2001 Feb;15(1):48-55. PubMed PMID: 11293924.

15: Post MS, Hendriks DF, Van Der Mooren MJ, Van Baal WM, Leurs JR, Emeis JJ, Kenemans P, Stehouwer CD. Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo- controlled, 12-week study in early postmenopausal women. J Intern Med. 2002 Mar;251(3):245-51. PubMed PMID: 11886484.

16: Bouchard P, De Cicco-Nardone F, Spielmann D, Garcea N; Trimegestone 301 Study Group. Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17beta-estradiol/trimegestone versus 1 or 2 mg 17beta-estradiol/norethisterone acetate in postmenopausal women. Gynecol Endocrinol. 2005 Sep;21(3):142-8. PubMed PMID: 16353319.

17: Gambacciani M, Spielmann D, Genazzani AR. Efficacy on climacteric symptoms of a continuous combined regimen of 1 mg 17beta-estradiol and trimegestone versus two regimens combining 1 or 2 mg 17beta-estradiol and norethisterone acetate. Gynecol Endocrinol. 2005 Aug;21(2):65-73. PubMed PMID: 16294457.

18: Winneker RC, Bitran D, Zhang Z. The preclinical biology of a new potent and selective progestin: trimegestone. Steroids. 2003 Nov;68(10-13):915-20. Review. PubMed PMID: 14667983.

19: Warming L, Ravn P, Spielman D, Delmas P, Christiansen C. Trimegestone in a low-dose, continuous-combined hormone therapy regimen prevents bone loss in osteopenic postmenopausal women. Menopause. 2004 May-Jun;11(3):337-42. PubMed PMID: 15167314.

20: Lepescheux L, Secchi J, Gaillard-Kelly M, Miller P. Effects of 17 beta-estradiol and trimegestone alone, and in combination, on the bone and uterus of ovariectomized rats. Gynecol Endocrinol. 2001 Aug;15(4):312-20. PubMed PMID: 11560106.